← Leaderboards
Katherine Doerig
University Of Pennsylvania
$134,028
Attributed
$134,028
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $49K · FY2023–25$50K$37.5K$25K$12.5K$0
'23
'24
'25
Funding mix
By agency
NIH$134,028 · 1
By mechanism
F31$134,028 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Stephen G Emerson$28,932,839
- Daniel James Rader$77,348,993
- Daniel Patrick Kelly$33,087,106
- Lewis A Chodosh$38,386,361
- Charles P Emerson$35,198,488
Others in their field
Other Rising Stars on “Antagonist”
- Xuping Xie · University Of Texas Med Br Galveston$13,737,799
- Andrew Gardiner · Libero Pharma Limited$6,351,015
- Charles Daniel Meyers · Tempero Bio, Inc.$5,310,920
- Ian Gurrell · Astrazeneca Pharmaceuticals, Lp$5,256,914
- Mark Sorenson · Nirsum Laboratories, Inc.$4,866,388
- David G Brooks · Boston Immune Technologies And Therapeutics, Inc.$3,974,764
Research focus
AntagonistAccelerationBraf GeneCancer CellCancer EtiologyBenchmarkingCancer TherapyCancer TypeCell DeathCell LineCell ProliferationConflict (Psychology)Cancer GenomeDriver MutationEpidermal Growth Factor ReceptorFitnessFrap1 GeneGenesGeneticGenetic EpistasisGenome SequencingGenotypeGrowthHistone Methyltransferase
Grant awards (3)
Paradoxical Effects of SETD2 Inactivation in EGFR- and KRAS-driven Lung Adenocarcinoma$37,360
F31 · FY2025 · CA · contact PI
Paradoxical Effects of SETD2 Inactivation in EGFR- and KRAS-driven Lung Adenocarcinoma$48,974
F31 · FY2024 · CA · contact PI
Paradoxical Effects of SETD2 Inactivation in EGFR- and KRAS-driven Lung Adenocarcinoma$47,694
F31 · FY2023 · CA · contact PI